Results 251 to 260 of about 186,825 (346)

Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N -methyl- d -aspartic acid receptor activity

, 1998
Eric S. Levine, Robert A. Crozier, Ira B. Black, Mark R. Plummer   +3 more
openalex   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis. [PDF]

BMC Anesthesiol
Dehbozorgi M, Fereidooni F, Bozorgmehr R, Bagherpour JZ, Shafiee A, Mohammadi I, Amini MJ, Seighali N, Jafarabady K, Rajai Firouzabadi S, Akbarzade D, Bahri RA.   +11 more
europepmc   +1 more source

Retinoic Acid Induces Apoptosis in PC12 Cells Independent of Neurotrophic Factors [PDF]

, 1997
Liqi Tong, Karin Werrbach‐Perez, J. Regino Perez‐Polo   +2 more
openalex   +1 more source

Treatment Selection and Prioritization for the EJS ACT‐PD MAMS Trial Platform

Movement Disorders, EarlyView.
Abstract Background There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment of putative DMTs through a multi‐arm multistage (MAMS) trial, testing several treatments against a common ...
Cristina Gonzalez‐Robles, Dilan Athauda, Thomas R. Barber, Roger A. Barker, David T. Dexter, Susan Duty, Romy Ellis‐Doyle, Sonia Gandhi, Joel Handley, Edwin Jabbari, Keith Martin, Kevin McFarthing, Georgia Mills, Heather Mortiboys, Stephen Mullin, Rebecca Petty, Esther Sammler, Paula Scurfield, Simon R.W. Stott, George K. Tofaris, Li Wei, Caroline H. Williams‐Gray, Alan Wong, Marie‐Louise Zeissler, Richard K. Wyse, Camille B. Carroll, Thomas Foltynie, Oliver Bandmann, Anthony H.V. Schapira, on behalf of the EJS ACT‐PD Consortium   +29 more
wiley   +1 more source

A novel probiotic formula, BLLL, ameliorates chronic stress-induced depression-like behaviors in mice by reducing neuroinflammation and increasing neurotrophic factors. [PDF]

Front Pharmacol
Ye M, Ji F, Huang C, Li F, Zhang C, Zhang Y, Wang R, Ma K, Lu X, Wang H.   +9 more
europepmc   +1 more source

Transformation by Ras Suppresses Expression of the Neurotrophic Growth Factor Pleiotrophin [PDF]

, 1997
Michael J. Corbley
openalex   +1 more source

Intraputaminal Delivery of Adeno‐Associated Virus Serotype 2–Glial Cell Line–Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Glial cell line–derived neurotrophic factor (GDNF) is required for development and survival of dopaminergic neurons. A previous trial evaluating lower‐dose adeno‐associated virus serotype 2–GDNF (AAV2‐GDNF) bilateral intraputaminal infusion in participants with advanced Parkinson's disease (PD) achieved 26% mean putaminal coverage ...
Amber D. Van Laar, Chadwick W. Christine, Nicolás Phielipp, Paul S. Larson, J. Bradley Elder, Aristide Merola, Waldy San Sebastian, Massimo S. Fiandaca, Adrian P. Kells, Michael E. Wisniewski, Krystof S. Bankiewicz   +10 more
wiley   +1 more source

Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults. [PDF]

Neurology
Weinstein G, Kojis DJ, Ghosh S, Beiser AS, Seshadri S.   +4 more
europepmc   +1 more source

Neuronally‐Derived Extracellular Vesicles Transforming Growth Factor Beta‐1 Levels in Progressive Supranuclear Palsy

Movement Disorders, EarlyView.
Abstract Background Differentiating progressive supranuclear palsy (PSP) from other parkinsonian disorders may be challenging. Objectives To investigate the role of transforming growth factor beta‐1 (TGFβ1) in PSP. Methods A total of 33 PSP, 39 Parkinson's disease (PD), 8 multiple system atrophy (MSA) patients, and 50 healthy controls (HC) were ...
Selena Mimmi, Elvira Immacolata Parrotta, Anna Maria Tolomeo, Domenico Maisano, Valentina Crapella, Elisabetta Pingitore, Khushboo Fatima, Anna Maria Zimbo, Mariagrazia Talarico, Costanza Maria Cristiani, Luana Scaramuzzino, Desirèe Valente, Clara Zannino, Gianni Cuda, Aldo Quattrone, Enrico Iaccino, Andrea Quattrone   +16 more
wiley   +1 more source